Infection/RespiratoryHigh-flow nasal therapy in adults with severe acute respiratory infection: A cohort study in patients with 2009 influenza A/H1N1v☆
Introduction
Severe acute respiratory infection (SARI) due to pandemic 2009 influenza A/H1N1v infection was characterized by a rapid acute respiratory failure (ARF), preceded by 3 to 5 days of flu-like symptoms. Data from large cohorts during the pandemic period indicated that 30% of all hospital-admitted patients required intensive care unit (ICU) admission with more than 60% of them being subsequently mechanically ventilated [1], [2].
High-flow nasal cannula (HFNC) O2 therapy is the newest and least known noninvasive option for the clinical management of patients with ARF. Current heated/humidified high flow (up to 50 L/min) devices have achieved a great degree of efficacy and comfort in delivering high-flow oxygen compared with conventional oxygen therapy [3]. Furthermore, improvement in oxygenation with HFNC has been described in patients with mild to severe ARF [3], [4], [5]. For these reasons and the comfort provided to the patient, HFNC O2 therapy appears to be an innovative modality for early treatment of adult patients with severe ARF. Although it has the potential to reduce the need of mechanical ventilation (MV), its indications remain speculative. Information on SARI due to influenza A/H1N1v is limited to 5 patients [4].
Our hypothesis was that HFNC O2 therapy could be an efficient noninvasive intervention and that it might alleviate the need for MV in some patients with SARI. To evaluate this hypothesis, the clinical course of nonintubated patients with SARI was recorded, with specific focus on those receiving HFNC O2 therapy who were also compared with control patients already mechanically ventilated on admission. Primary end points were the need for MV and ICU mortality. Secondary objectives of the analysis were to identify a subset of patients most likely to benefit from HFNC O2 therapy and to anticipate outcomes.
Section snippets
Methods
This study represents a post hoc analysis of a prospectively assessed cohort of adult patients admitted with ARF due to 2009 influenza A/H1N1v infection (in the general ICU of Vall d'Hebron University Hospital in Barcelona, a large tertiary university hospital) from September 1, 2009, to January 31, 2011. Patients reported in this study were also reported to a large national registry, which received ethics board approval in July 2009 (ref. 07/J23). Informed consent was waived because of the
Results
Thirty-five adult patients with confirmed 2009 influenza A/H1N1v infections required ICU admission because of SARI with severe hypoxemia or acute respiratory distress syndrome. All patients received oral oseltamivir and parenteral antibiotics. Ten patients (28.6%) already required intubation before ICU admission. Data for intubated patients were compared with patients requiring HFNC O2 treatment. High-flow nasal cannula O2 therapy patients were significantly younger (37 [29-47] vs 50 [44-56]
Discussion
This is the first study reporting HFNC used in a series of adult patients as early therapy for severe ARF caused by 2009 influenza A/H1N1v infection. Our findings suggest that all patients with inotropes required intubation. Furthermore, patients without cardiovascular compromise and an RR above 30 breaths per minute on conventional oxygen therapy, upon ICU admission, may benefit of a HFNC trial. Six hours after onset of treatment, failing patients demonstrated worse oxygenation (Pao2/Fio2 < 100
References (21)
- et al.
Pandemic influenza A (H1N1)v in the intensive care unit: what have we learned?
Arch Bronconeumol
(2010) - et al.
First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain
Med Intensiva
(2011) - et al.
First influenza season after the 2009 pandemic influenza: characteristics of ICU admissions in adults and children in Vall d'Hebron Hospital
Clin Microbiol Infect
(2012) - et al.
Impact of obesity in patients infected with 2009 influenza A (H1N1)
Chest
(2011) - et al.
Oxygen delivery through high-flow nasal cannulae increase end-expiratory lung volume and reduce respiratory rate in post-cardiac surgical patients
Br J Anaesth
(2011) - et al.
Research in high flow therapy: mechanisms of action
Respir Med
(2009) - et al.
The effects of high-flow vs low-flow oxygen on exercise in advanced obstructive airways disease
Chest
(2004) - et al.
High-flow oxygen therapy in acute respiratory failure
Respir Care
(2010) - et al.
Beneficial effects of humidified high flow nasal oxygen in critical care patients: a prospective pilot study
Intensive Care Med
(2011) - et al.
A preliminary randomized controlled trial to assess effectiveness of nasal high-flow oxygen in intensive care patients
Respir Care
(2011)
Cited by (146)
Latest developments in early diagnosis and specific treatment of severe influenza infection
2023, Journal of Intensive MedicineCovid-19 severe hypoxemic pneumonia: A clinical experience using high-flow nasal oxygen therapy as first-line management
2021, Respiratory Medicine and ResearchAcute respiratory distress syndrome
2021, The LancetEmergency Department Management of Severe Hypoxemic Respiratory Failure in Adults With COVID-19
2021, Journal of Emergency Medicine
- ☆
Conflicts of interest: Dr Masclans and Dr Roca have received honoraria as lecture fees from Fisher & Paykel. This study has been funded in part with CIBERES funding (PCI Neumonia) and AGAUR (2009SGR01226). Fisher & Paykel did not have access to the manuscript and have not participated neither in the study design or interpretation of results. Dr Pérez, Dr Poulakou, Dr Souto, Dr Laborda, Dr Balcells, and Dr Rello have no conflict of interest to disclose.